Technology | Breast Imaging | April 07, 2016

MarginProbe Modification Receives FDA Pre-Market Approval

Device adds more powerful CPU, updated screen as part of changes to meet requirements for European sale

Dune Medical, MarginProbe, FDA PMA approval, breast cancer detection

April 7, 2016 — Dune Medical Devices has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) to make modifications to MarginProbe, an FDA-approved device for real-time detection of cancer in breast conserving surgery. The modifications will incorporate new features that will enable the device to be compliant with the recent changes in Restriction of Hazardous Substances (RoHs) requirements necessary to sell into the European Union (EU) market.  

The new upgrade includes manufacturing MarginProbe 1.2 to meet changes in the RoHs requirements, which are expected to be adopted by the United States in the near future. In addition, Dune Medical Device equipped the instrument with a new, updated screen for displaying the results and an upgraded operating system.

Margin Probe 1.2R also contains a much stronger and more modern central processing unit (CPU), allowing the medical device to support anticipated evolutions in both technology and operating systems.

Traditionally, one in four women who undergo a lumpectomy procedure require a re-excision to remove cancer missed during the first procedure. That number is reduced by 51 percent when MarginProbe is used during the initial procedure.

For more information: www.dunemedical.com

Related Content

SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...